Stocktoria
ARVINAS, INC. ARVN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-09-27
ARVINAS, INC. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $262.6M | $263.4M | $78.5M | $131.4M | $53.6M | $25.9M | $43.0M | $14.3M | $7.6M |
| R&D expense | $285.2M | $348.2M | $379.7M | $315.0M | $180.4M | $108.4M | $67.2M | $45.2M | $28.8M |
| Operating income | -$118.5M | -$250.2M | -$401.5M | -$263.2M | -$188.4M | -$120.8M | -$51.5M | -$43.8M | -$24.8M |
| Interest expense | — | $0 | $0 | $0 | $0 | $100,000 | $100,000 | $57,440 | $50,357 |
| Income tax | $300,000 | $600,000 | $900,000 | $20.9M | $0 | $0 | $0 | $0 | $0 |
| Net income | -$80.8M | -$198.9M | -$367.3M | -$282.5M | -$191.0M | -$119.3M | -$70.3M | -$41.5M | -$24.0M |
| EPS (diluted) | $-1.14 | $-2.77 | $-6.62 | $-5.31 | $-3.82 | $-3.02 | $-2.13 | — | — |
| Operating cash flow | -$273.8M | -$259.3M | -$347.8M | -$273.5M | $559.4M | -$89.7M | -$40.6M | -$16.1M | $5.1M |
| Free cash flow | -$275.7M | -$261.1M | -$350.7M | -$280.3M | $554.7M | -$96.1M | -$46.9M | -$18.9M | $4.1M |
| Cash & equivalents | $142.9M | $100.5M | $311.7M | $81.3M | $108.3M | $588.4M | $9.2M | $3.2M | $30.9M |
| Total assets | $717.9M | $1.1B | $1.3B | $1.3B | $1.6B | $717.4M | $301.6M | $199.3M | $66.8M |
| Total liabilities | $284.0M | $529.7M | $644.6M | $703.9M | $799.9M | $75.2M | $75.0M | $62.6M | $66.6M |
| Shareholders' equity | $433.9M | $561.7M | $660.0M | $564.9M | $781.7M | $642.2M | $226.6M | $136.6M | -$61.2M |
Growth · year-over-year · Revenue CAGR 55.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -0.3% | +235.5% | -40.3% | +145.1% | +106.9% | -39.8% | +200.2% | +89.0% | — |
| Free cash flow growth | — | — | — | -150.5% | — | — | — | -562.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.